Literature DB >> 27058780

Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery.

Yuyang Kuang1, Xutao Jiang1, Yu Zhang1, Yifei Lu1, Haojun Ma1, Yubo Guo1, Yujie Zhang1, Sai An1, Jianfeng Li1, Lisha Liu1, Yinhao Wu1, Jianying Liang2, Chen Jiang1,3.   

Abstract

Compared with peripheral tumors, glioma is very difficult to treat, not only because it has general features of tumor but also because the therapy has been restricted by the brain-blood barrier (BBB). The two main features of tumor growth are angiogenesis and proliferation of tumor cells. RNA interference (RNAi) can downregulate VEGF overexpression to inhibit tumor neovascularization. Meanwhile, doxorubicin (DOX) has been used for cytotoxic chemotherapy to kill tumor cells. Thus, combining RNAi and chemotherapy has been regarded as a potential strategy for cancer treatment. However, the BBB limits the shVEGF-DOX codelivery system to direct into glioma. Here, a smart drug delivery system modified with a dual functional peptide was established, which could target to transferrin receptor (TfR) overexpressing on both the BBB and glioma. It showed that the dual-targeting delivery system had high tumor targeting efficiency in vitro and in vivo.

Entities:  

Keywords:  RNA interference; combination therapy; doxorubicin; glioma dual targeting; transferrin

Mesh:

Substances:

Year:  2016        PMID: 27058780     DOI: 10.1021/acs.molpharmaceut.6b00051

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

Review 1.  Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.

Authors:  Gabriel Nery de Albuquerque Rego; Arielly da Hora Alves; Mariana Penteado Nucci; Javier Bustamante Mamani; Fernando Anselmo de Oliveira; Lionel Fernel Gamarra
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

2.  HAI Peptide and Backbone Analogs-Validation and Enhancement of Biostability and Bioactivity of BBB Shuttles.

Authors:  Pol Arranz-Gibert; Roger Prades; Bernat Guixer; Simón Guerrero; Eyleen Araya; Sonia Ciudad; Marcelo J Kogan; Ernest Giralt; Meritxell Teixidó
Journal:  Sci Rep       Date:  2018-12-18       Impact factor: 4.379

3.  Peptide Mediated Brain Delivery of Nano- and Submicroparticles: A Synergistic Approach.

Authors:  Mark McCully; Macarena Sanchez-Navarro; Meritxell Teixido; Ernest Giralt
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

4.  Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.

Authors:  Annie Arguello; Cathal S Mahon; Meredith E K Calvert; Darren Chan; Jason C Dugas; Michelle E Pizzo; Elliot R Thomsen; Roni Chau; Lorna A Damo; Joseph Duque; Meng Fang; Tina Giese; Do Jin Kim; Nicholas Liang; Hoang N Nguyen; Hilda Solanoy; Buyankhishig Tsogtbaatar; Julie C Ullman; Junhua Wang; Mark S Dennis; Dolores Diaz; Kannan Gunasekaran; Kirk R Henne; Joseph W Lewcock; Pascal E Sanchez; Matthew D Troyer; Jeffrey M Harris; Kimberly Scearce-Levie; Lu Shan; Ryan J Watts; Robert G Thorne; Anastasia G Henry; Mihalis S Kariolis
Journal:  J Exp Med       Date:  2022-02-28       Impact factor: 14.307

Review 5.  Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches.

Authors:  Chad A Caraway; Hallie Gaitsch; Elizabeth E Wicks; Anita Kalluri; Navya Kunadi; Betty M Tyler
Journal:  Polymers (Basel)       Date:  2022-07-21       Impact factor: 4.967

6.  Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment.

Authors:  Zakia Belhadj; Changyou Zhan; Man Ying; Xiaoli Wei; Cao Xie; Zhiqiang Yan; Weiyue Lu
Journal:  Oncotarget       Date:  2017-05-18

7.  Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity.

Authors:  Lisha Liu; Qinjun Chen; Chunhui Ruan; Xinli Chen; Yu Zhang; Xi He; Yujie Zhang; Yifei Lu; Qin Guo; Tao Sun; Hao Wang; Chen Jiang
Journal:  Theranostics       Date:  2018-04-18       Impact factor: 11.556

Review 8.  Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges.

Authors:  Victor M Pulgar
Journal:  Front Neurosci       Date:  2019-01-11       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.